March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
The Effect of IL-6 Neutralization on Corneal Allograft Survival
Author Affiliations & Notes
  • Shilpa Kodati
    Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • William Stevenson
    Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Masahiro Omoto
    Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Takaaki Hattori
    Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
    Ophthalmology, Tokyo Medical University, Shinjuku, Japan
  • Thomas H. Dohlman
    Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Daniel R. Saban
    Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Sunil K. Chauhan
    Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Reza Dana
    Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  Shilpa Kodati, None; William Stevenson, None; Masahiro Omoto, None; Takaaki Hattori, None; Thomas H. Dohlman, None; Daniel R. Saban, None; Sunil K. Chauhan, None; Reza Dana, None
  • Footnotes
    Support  NIH Grant EY12963; Richard Lindstrom Grant, Eye Bank Association of America.
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2378. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shilpa Kodati, William Stevenson, Masahiro Omoto, Takaaki Hattori, Thomas H. Dohlman, Daniel R. Saban, Sunil K. Chauhan, Reza Dana; The Effect of IL-6 Neutralization on Corneal Allograft Survival. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2378.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Interleukin-6 (IL-6) has emerged as a critical regulator of T-helper 17 (Th17)/T regulatory (Treg) balance. In the presence of TGF-β, IL-6 inhibits Treg differentiation, favoring the development of the Th17 lineage. Utilizing a murine model of penetrating keratoplasty, we investigated the effect of IL-6 neutralization on corneal allograft survival.

Methods: : Fully disparate corneal grafts from 8-week C57BL/6 male donor mice were orthotopically transplanted into age and gender matched BALB/c recipient mice (n=10). In order to characterize the presence of IL-6 post transplantation, the expression of IL-6 in corneal allografts was quantified. Recipient mice were injected via the intraperitoneal route with anti-IL-6 or isotype antibodies daily up to day 7, and subsequently on alternate days. Survival was assessed using a clinical scoring system examining graft opacity.

Results: : Real-time PCR was performed to quantify the mRNA expression of IL-6 and IL-17 in accepted and rejected allografts at week 3. A 800-fold increase in mRNA levels of IL-6 was detected in rejected allografts compared to accepted allografts. Similarly, over a 9- fold difference in the mRNA expression of IL-17 was observed in rejected grafts. Graft survival was evaluated up to week 4 in anti-IL-6 antibody and isotype treated groups. Transplanted mice at week 4 demonstrated 80% graft survival compared with 40% in the control group.

Conclusions: : Our data shows up-regulation of both IL-6 and IL-17 in rejected allografts and prolonged graft survival following IL-6 neutralization.

Keywords: transplantation • cornea: basic science • immunomodulation/immunoregulation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×